Results 121 to 130 of about 84,026 (244)

Efficacy of open-label placebos for premenstrual syndrome: a randomised controlled trial

BMJ Evidence-Based Medicine
ObjectiveTo investigate the efficacy and safety of open-label placebos (OLP) in premenstrual syndrome (PMS).DesignRandomised controlled trial.SettingSwitzerland, 2018–2020.Participants150 women (18–45 years of age) with PMS or premenstrual dysphoric disorder.InterventionRandom assignment (1:1:1) to treatment as usual (TAU), OLP without treatment ...
Antje Frey Nascimento, Jens Gaab, Bojana Degen, Mareike Rytz, Anja Holder, Dilan Sezer, Sarah Buergler, Andrea H Meyer, Irving Kirsch, Joe Kossowsky, Cosima Locher   +10 more
openaire   +2 more sources

Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial

Arthritis &Rheumatology, EarlyView.
Objective Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA. Methods This was a post hoc analysis of a phase 3, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in ...
Hermine I. Brunner, Ekaterina Alexeeva, Marcia Bandeira, Ruy Carrasco, Jeffrey Chaitow, Peter Chiraseveenuprapund, Tracy V. Ting, Muferet Erguven, Beth Gottlieb, Sheila Knupp Oliveira, Pooja N. Patel, Seza Ozen, Claudia Saad Magalhaes, Inmaculada Calvo Penadés, David Gruben, Rebecca Germino, Holly B. Posner, Lori Stockert, Alberto Martini, Daniel J. Lovell, Nicolino Ruperto, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)   +21 more
wiley   +1 more source

Study protocol: combined N-of-1 trials to assess open-label placebo treatment for antidepressant discontinuation symptoms [FAB-study]. [PDF]

BMC Psychiatry, 2023
Müller A, Konigorski S, Meißner C, Fadai T, Warren CV, Falkenberg I, Kircher T, Nestoriuc Y.   +7 more
europepmc   +1 more source

Open-label placebo treatment for reducing overeating in children: A study protocol for a randomized clinical trial with an app-assisted approach. [PDF]

Contemp Clin Trials Commun, 2023
Schienle A, Unger I.
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Measuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease

Arthritis &Rheumatology, Accepted Article.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon, Rui Xiao, Daniel J. Lovell, Edward Oberle, Matthew L. Stoll, Nancy A. Chauvin, Michael L. Francavilla, Walter P. Maksymowych, Pamela F. Weiss   +8 more
wiley   +1 more source

Study protocol: randomised controlled trial of conditioned open-label placebo (COLP) for perioperative pain management in patients with head and neck cancer. [PDF]

BMJ Open, 2023
Trakimas DR, Colloca L, Fakhry C, Tan M, Khan Z, Vosler PS.   +5 more
europepmc   +1 more source

Open-Label-Placebos zur Appetitreduktion bei Kindern mit Übergewicht und Adipositas: Eine Studie zur Wirksamkeit und eine Umfrage zur Einstellung gegenüber Open-Label-Placebos

, 2023
Übergewicht und Adipositas im Kindesalter gehen mit einer Vielzahl chronischer Erkrankungen und einer erhöhten Mortalität bereits im jungen Erwachsenenalter einher. In Österreich ist jedes vierte Kind zwischen acht und neun Jahren von Übergewicht oder Adipositas betroffen.
openaire  

The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Arthritis &Rheumatology, EarlyView.
Objective Ear, nose, and throat (ENT) manifestations are common in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There is an unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)–AAV. In a zebrafish model, niclosamide inhibits PR3‐induced granuloma formation.
Benjamin Lim, Wendi Qian, Francis Dowling, Alan Salama, Rona M Smith   +4 more
wiley   +1 more source

Placebos Are Part of the Solution, Not the Problem. An Exemplification of the Case of Antidepressants in Pediatric Chronic Pain Conditions

Frontiers in Psychiatry, 2020
Cosima Locher, Cosima Locher, Cosima Locher, Jens Gaab, Charlotte Blease, Marc Inderbinen, Linda Kost, Helen Koechlin, Helen Koechlin   +8 more
doaj   +1 more source